RALEIGH, N.C., Jan. 16, 2018 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (PRAH) is pleased to announce the opening of a new clinic in Salt Lake City, Utah. The new facility will offer full service early stage clinical research capabilities for healthy participants and specialized patient populations. It allows for the consolidation of four existing locations in the Salt Lake area into one cohesive facility for both inpatient and outpatient services.
“This new space significantly increases our clinical capabilities,” said Mark Slama, Executive Director Clinical Research Services. “We now have over 65,000 square feet of space, an increase of more than 20,000 square feet from our previous clinic, and we have the ability to accommodate 120 clinical research participants, which expands our capacity by 20 percent.”
The new facility will enhance PRA’s capabilities in executing innovative studies involving new drug candidates for challenging psychiatric and neurological disorders as well as Human Abuse Potential (HAP) studies.
“PRA’s investment in early development studies allows us to expand our sleep disorder and pain related studies,” added Eddie Caffrey, Senior Vice President, Early Development Services. “The new clinic will include an on-site surgical suite equipped for cerebrospinal fluid sampling and post-surgical pain and device implantation allowing us to deliver high quality scientific results.”
The clinic will house a state of the art GCP-compliant pharmacy as well as a lab with larger centralized processing capabilities. Centrally located in Salt Lake City, the new clinic is conveniently located across the street from St. Mark’s Hospital, a full-service trauma hospital.
PRA’s Salt Lake City research activities typically include studies in addiction, pain, psychiatry, neurology, pediatric and infectious disease services.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world’s leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over 15,000 employees worldwide. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com.
INQUIRIES: Christine Rogers, Manager – Public Relations, Corporate Communications EMAIL: email@example.com PHONE: +1 919.786.8463